IONS

In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Ionis Pharmaceuticals (IONS - Research Report), with a price target of $60.00. The company's shares closed yesterday at $41.65.According to TipRanks, Stringer is a 3-star analyst with an average return of 2.6% and a 44.98% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Alnylam Pharma, and Ionis Pharmaceuticals.Ionis Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $49.10.See today’s best-performing stocks on TipRanks >>Based on Ionis Pharmaceuticals' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $133.
https://www.tipranks.com/news/blurbs/needham-sticks-to-its-buy-rating-for-ionis-pharmaceuticals-ions?utm_source=advfn.com&utm_medium=referral